Cresco Labs (CL) EGM 2025 summary
Event summary combining transcript, slides, and related documents.
EGM 2025 summary
23 Apr, 2026Opening remarks and agenda
Meeting called to order with rules for virtual participation and electronic voting outlined.
Notice of meeting and related materials were distributed to shareholders of record as of August 1, 2025.
Quorum confirmed and meeting declared properly constituted.
Meeting held on September 16, 2025, to address annual general and special matters.
Specific resolutions to be voted on
Number of directors set at seven for the ensuing year.
Election of directors as nominated in the Management Information Circular, with all seven approved by majority vote.
Appointment of Baker Tilly U.S., LLP as auditor for the ensuing year and authorization for the board to fix remuneration.
Approval of the corporation's Award Exchange Program for certain employees.
Corporate governance
Secretary and scrutineer appointed for the meeting.
Advance notice policy followed for director nominations.
Latest events from Cresco Labs
- Q1 2026 revenue was $151.3M with $33M adjusted EBITDA and expanded dispensary presence.CL
Q1 20268 May 2026 - All resolutions, including board elections and incentive plan changes, passed with strong support.CL
EGM 202423 Apr 2026 - Q4 2025 revenue was $162M with margin gains, but net loss was driven by impairment charges.CL
Q4 20255 Mar 2026 - Q2 saw margin and cash flow gains, with growth expected as adult-use markets expand.CL
Q2 20242 Feb 2026 - Q3 2024 saw record cash flow, margin gains, and top market share amid strategic growth moves.CL
Q3 202415 Jan 2026 - Margin and cash flow gains drive growth and expansion despite revenue decline and tax charges.CL
Q4 202425 Dec 2025 - Vertically integrated U.S. cannabis operator launches multi-security shelf offering amid regulatory risks.CL
Registration Filing29 Nov 2025 - Q1 2025 delivered $166M revenue, strong cash flow, and market leadership despite margin pressure.CL
Q1 202525 Nov 2025 - Q2 2025 revenue hit $164M, 25% EBITDA margin, and debt refinancing supports future growth.CL
Q2 202523 Nov 2025